FLORENCE, Italy — As-needed administration of a corticosteroid implant may enhance stability of visual outcomes in patients with diabetic macular edema, according to a study. In phase 3 studies, the Ozurdex dexamethasone implant (Allergan) administered at fixed 6-month intervals proved effective, but a small, gradual decline of vision was seen after the first 3 months as the effects of the drug started wearing off.
HEIDELBERG, Germany–(BUSINESS WIRE)–NovaTears, from Novaliq GmbH, was found to significantly improve four of five measures associated with evaporative dry eye disease, new research shows. It was also shown to be safe and well tolerated.
Dextenza showed promising results in a phase 2 exploratory clinical trial in the treatment of inflammatory dry eye disease, Ocular Therapeutix announced in a press release.The prospective, randomized, vehicle controlled phase 2 trial, conducted at two …
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals (NASDAQ: ITEK) today announced it will host its first R&D Day from 10:00 a.m. to 1:30 p.m. EST on December 17th in New York City.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/6fbvnt/global) has announced the addition of the “Global Intraocular Lens (IOL) Market: Trends, Opportunities and Forecasts (2015-2020F) – (By Type – Standard and…
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data from its Raindrop® Near Vision Inlay for the treatment of presbyopia was the subject of two presentations at the 2015 OIS@AAO conference, held last month in Las Vegas. At the conference, John Kilcoyne, ReVision Optics President and Chief Executive Officer, presented an overview of clinical data from 344 patients followed for 24 months